Athersys saw no growth in patent filings and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Athersys‘s patent filings and grants. Buy the databook here.
Athersys has been focused on protecting inventions in Japan(JP) with one publication in Q2 2024
The Japan(JP) Patent Office dominates the patent grants with nearly 50% of grants. The Japan(JP), and United States(US) patent Office are among the top ten patent offices where Athersys is filings its patents. Among the top granted patent authorities, Athersys has 50% of its grants in Japan(JP) and 50% in United States(US).
Patents related to cell & gene therapy and rare diseases lead Athersys's portfolio
Athersys has the highest number of patents in cell & gene therapy followed by, rare diseases and industrial automation. For cell & gene therapy no patents were filed and 25% of patents were granted in Q2 2024.
Household appliances related patents lead Athersys portfolio followed by laboratory equipment, and stroke
Athersys has highest number of patents in household appliances followed by laboratory equipment, stroke, multiple sclerosis, and traumatic brain injury.
For comprehensive analysis of Athersys's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.